Maddi Hebebrand, MC, Associate Editor

His presentation at South Beach Symposium will feature Zirwas’ insights on JAK inhibitors, eczema treatments, and emerging therapies.

Goldberg noted combination treatments that integrate radiofrequency, ultrasound, and muscle stimulation could improve patient outcomes.

Catch up on coverage from the first day of the 2025 South Beach Symposium held in Miami Beach, Florida.

“The most important tip as a physician, when you talk to the patient, sit down. Even if you sit down for 5 minutes, it's worth almost 5 hours,’ Leon Kircik, MD, said in his interview with Dermatology Times at SBS 2025.

Nada Elbuluk, MD, MSc, emphasizes that medical treatments remain first-line for vitiligo, but stable cases may benefit from surgical options.

Ablon covered all aspects of getting involved in clinical research, such as budgeting, recruiting, and analyzing data.

According to Silverberg, emotional resilience, social support, and purposeful activities help adolescents cope with acne-related stress.

Nanette Silverberg, MD, highlights new dermatology advancements and the significance of conferences like MOPD in shaping the future of treatment.

Dermatology Times staff will be onsite covering SBS 2025 with expert insights, interviews, and breaking news.

In an interview ahead of the main event, Ablon shared her excitement for SBS and listening in on presentations from industry leaders.

We want to know: Will you be attending the symposium in Miami Beach this week?

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

In his presentation at Winter Clinical Miami, Del Rosso covered a variety of topics including refractory pediatric vitiligo.

Biologic coordinators play a key role in managing insurance approvals and ensuring coverage details are confirmed quickly, often within 48 hours.

Explore the top headlines of the week including innovation in scalp treatment, therapeutic updates in rosacea, and acne vulgaris insights from James Del Rosso, DO.

In an interview with Dermatology Times, Del Rosso shared the latest in the treatment landscape for patients with Darier disease.

A recent study found standard burn assessment tools often fail to accurately evaluate injuries in darker skin tones, leading to misdiagnosis and delays.

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

Del Rosso outlined new and off-label therapies for the disease that he shared in his presentation at Winter Clinical Miami.

In an interview with Dermatology Times, Del Rosso gave insight on off-label therapies that could be used to treat granuloma annulare.

The meta-analysis found that HA fillers enhance skin hydration and glow, but do not significantly impact elasticity.

James Del Rosso, DO, explored the treatment landscape and the importance of regular eye exams for patients with AD.

As a part of his presentation at Winter Clinical Miami, Del Rosso discussed new and emerging therapies for acne vulgaris.

Noor noted patients benefit from in-house injection services, avoiding the inconvenience of traveling to off-site centers.

James Del Rosso, DO, shared insights on existing and upcoming therapies for seborrheic dermatitis.

Explore the top headlines of the week including clinical trial updates, social media hair trends, and expert insights.

QRX003 mimics the LEKTI protein to strengthen skin barriers and alleviate symptoms in patients with Netherton Syndrome.

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

AP31, a novel micropeptide, delivers anti-aging and anti-inflammatory benefits, improving skin firmness, lifting, and reducing wrinkles.